Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma

Author： Merin Noah M.   Kelly Kevin R.  

Publisher： MDPI

E-ISSN： 1424-8247|8|1|1-20

ISSN： 1424-8247

Source： Pharmaceuticals, Vol.8, Iss.1, 2014-12, pp. : 1-20

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics

By Chhabra Saurabh  

Pharmaceuticals, Vol. 10, Iss. 2, 2017-04 ,pp. : 40-40

MDPI

Access to resources Recommend Favorite

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma

By Ribatti Domenico  

Pharmaceuticals, Vol. 3, Iss. 4, 2010-04 ,pp. : 1225-1231

MDPI

Access to resources Recommend Favorite

CIK Cells and HDAC Inhibitors in Multiple Myeloma

By Stephan David   Weiher Hans   Schmidt-Wolf Ingo G.H.  

International Journal of Molecular Sciences, Vol. 18, Iss. 5, 2017-04 ,pp. : 945-945

MDPI

Access to resources Recommend Favorite

The Role of Immunotherapy in Multiple Myeloma

By Kocoglu Mehmet   Badros Ashraf  

Pharmaceuticals, Vol. 9, Iss. 1, 2016-01 ,pp. : 3-3

MDPI

Access to resources Recommend Favorite

Development of Novel Immunotherapies for Multiple Myeloma

By Al-Hujaily Ensaf M.   Oldham Robyn A. A.   Hari Parameswaran   Medin Jeffrey A.  

International Journal of Molecular Sciences, Vol. 17, Iss. 9, 2016-09 ,pp. : 1506-1506

MDPI

Access to resources Recommend Favorite